{
    "score": [
        1.0
    ],
    "extracted": [
        5
    ],
    "abstract": [
        "selecta biosciences earns daily media sentiment score of 0.12 ."
    ],
    "id": "287099.train",
    "article": [
        "news stories about selecta biosciences have trended somewhat positive on tuesday , accern sentiment analysis reports . the research firm identifies positive and negative media coverage by monitoring more than twenty million news and blog sources in real time . accern ranks coverage of publicly-traded companies on a scale of -1 to 1 , with scores closest to one being the most favorable . selecta biosciences earned a media sentiment score of 0.12 on accern 's scale . accern also assigned headlines about the company an impact score of 45.3310049621836 out of 100 , meaning that recent media coverage is somewhat unlikely to have an effect on the company 's share price in the immediate future . ",
        "several equities research analysts have recently issued reports on the stock . canaccord genuity raised their price objective on shares of selecta biosciences from $ 25.00 to $ 30.00 and gave the stock a `` buy '' rating in a research note on thursday , october 12th . zacks investment research upgraded shares of selecta biosciences from a `` sell '' rating to a `` hold '' rating in a research note on thursday , october 12th . valuengine downgraded shares of selecta biosciences from a `` hold '' rating to a `` sell '' rating in a research note on tuesday , september 26th . ",
        "finally , ubs downgraded shares of selecta biosciences from a `` buy '' rating to a `` neutral '' rating in a research note on thursday , november 9th . one research analyst has rated the stock with a sell rating , one has issued a hold rating and three have issued a buy rating to the company 's stock . selecta biosciences currently has an average rating of `` hold '' and an average price target of $ 23.50 . shares of selecta biosciences traded down $ 0.01 during trading on tuesday , hitting $ 10.00 . 142,000 shares of the stock traded hands , compared to its average volume of 119,154 . ",
        "the company has a debt-to-equity ratio of 0.32 , a quick ratio of 9.48 and a current ratio of 9.48 . selecta biosciences has a twelve month low of $ 8.70 and a twelve month high of $ 24.02 . in other selecta biosciences news , insider earl sands purchased 7,500 shares of the firm 's stock in a transaction on friday , november 17th . the shares were purchased at an average price of $ 10.26 per share , for a total transaction of $ 76,950.00 . following the completion of the purchase , the insider now directly owns 7,500 shares of the company 's stock , valued at $ 76,950 . ",
        "the acquisition was disclosed in a legal filing with the sec , which is available through the sec website . also , insider werner cautreels purchased 20,000 shares of the firm 's stock in a transaction on monday , november 13th . the shares were acquired at an average price of $ 9.31 per share , for a total transaction of $ 186,200.00 . following the purchase , the insider now directly owns 321,203 shares of the company 's stock , valued at $ 2,990,399.93 . the disclosure for this purchase can be found here . in the last quarter , insiders have acquired 90,098 shares of company stock worth $ 843,933 and have sold 355,658 shares worth $ 6,955,732 . ",
        "41.90 % of the stock is owned by insiders . warning : `` selecta biosciences earns daily media sentiment score of 0.12 '' was reported by watch list news and is the property of of watch list news . if you are accessing this piece on another website , it was illegally copied and republished in violation of u. s. and international trademark & copyright law . the legal version of this piece can be read at biosciences company profileselecta biosciences , inc is a clinical-stage biopharmaceutical company . the company using its synthetic vaccine particle technology to discover and develop targeted therapies that are designed to modulate the immune system to treat rare and serious diseases . ",
        "the company is engaged in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases .   "
    ]
}